Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) secures rights to tolimidone (formerly MLR-1023) through an agreement with Adhera Therapeutics, Inc. This exclusive, worldwide, sub-licensable license from Melior Pharmaceuticals I, Inc. allows Biodexa to develop, manufacture, and commercialize tolimidone. The move signifies Biodexa’s commitment to advancing innovative treatments for diseases with unmet medical needs, enhancing their pipeline of therapeutic products.
Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, is pleased to announce that it has entered into an agreement for the assignment of Adhera Therapeutics, Inc.’s (“Adhera’s”) rights to tolimidone (formerly coded MLR-1023) under an exclusive, worldwide, sub-licensable license from Melior Pharmaceuticals I, Inc. (“Melior”) to develop, manufacture, commercialize or otherwise exploit tolimidone.
Source: Bio Space